



## Editorial

### A Year in Review at *Clinical Therapeutics*: Looking Back as We Forge Ahead

Traditionally, the end of the year marks the time to reflect on both the achievements and challenges confronted in the past 12 months as we make new resolutions for the coming year. These moments of reflection are critical. Honoring successes is as important as acknowledging shortcomings. As 2022 comes to an end, we at *Clinical Therapeutics* reflect on a year of change, growth, and promises made to our readers to continually evolve in an ever-changing landscape of publishing on the emerging therapies and diagnostics integrating into patient care worldwide.

As we began the year, *Clinical Therapeutics* pledged to form a more diverse and inclusive editorial team.<sup>1</sup> Our authors and readers span the globe and should feel represented at the editorial level, particularly as we strive to advance personalized care<sup>2</sup> and highlight regional therapies and alternative medicine approaches.<sup>3</sup> This year, in addition to welcoming our new co–editor-in-chief, Dr Paul Beninger, we were thrilled to recruit our new gender medicine topic editors, Drs Angela Jarman and Sarah Perman, along with our new statistical editor, Dr Nicole Close. These additions led to a nearly 50% female representation on our editorial board. Our team recognizes the continued need to diversify our board to include both equal gender representation as well as ethnically and culturally diverse board members and affirm this commitment in the new year.

Recognizing the importance of both sex and gender on response to treatment, *Clinical Therapeutics* also reported on the need to consider sex when developing new drugs and assessing clinical response.<sup>4</sup> Assumptions that males and females will respond to and metabolize a drug similarly is outdated dogma that only belongs in years past. Rather, with each new emerging therapy, exploring safety and pharmacokinetic profiles across sex, gender, and age is our mandate. Furthermore, as personalized medicine approaches based on an individual's genetics and biology continue to emerge, use of advanced informatics and artificial intelligence technologies<sup>5</sup> will be imperative. *Clinical Therapeutics* highlighted each of these areas in 2022 and welcomes original research articles, reviews, commentaries, and editorials on personalized medicine and best treatment strategies.

The year 2022 also marked a time of addressing bias in scientific literature.<sup>6</sup> We tackled the paucity of published negative trials, as well as the influence of pharmaceutical companies on data reporting. Each of these areas results in blurring of the boundaries between fact and a biased interpretation of the facts.<sup>6</sup> We are committed to ensuring that all well-designed and expertly analyzed clinical trials have an important voice in the literature, regardless of outcomes.

Next, we updated our author guidelines to enhance transparency regarding the reporting of proprietary drugs, diagnostics, and interventions. Authors will now be required to release key information regarding drug structure and diagnostic platforms and algorithms before their work is considered for publication in *Clinical Therapeutics*. Our responsibility to the intellectual property rights of our authors shall not supersede our responsibility to provide full transparency to our readers.

As we look forward to 2023, we realize our journal's successes in 2022 are just the first steps in ensuring transparency, equity, and neutrality in scientific publications. The path forward to achieving these goals is winding and long but forms the foundation of our new resolutions in the coming year. From all of us at *Clinical Therapeutics*, we wish our readers a happy and healthy new year.



Jill L. Maron, MD, MPH

Division of Pediatrics, Women & Infants Hospital of Rhode Island, Providence, Rhode Island

## REFERENCES

1. Jhaveri R, Maron J. Our pledge to assemble a more diverse and inclusive editorial team at *Clinical Therapeutics*. *Clin Ther*. 2022;44:1–2.
2. Maron JL. Food for thought: is a personalized diet the optimal preventive medicine? *Clin Ther*. 2022;44:639–640.
3. Maron JL. Incorporating nature's therapies for improved health outcomes. *Clin Ther*. 2022;44:473.
4. Maron JL. Sex matters: the importance of generating sex-based care models. *Clin Ther*. 2022;44:4–5.
5. Maron JL. Impact of artificial intelligence on clinical decision-making in health care. *Clin Ther*. 2022;44:825–826.
6. Maron JL. Pledging to address scientific bias in published literature. *Clin Ther*. 2022;44:249–350.